Affiliation: University of Vermont
- Increased platelet expression of FcGammaRIIa and its potential impact on platelet reactivity in patients with end stage renal diseaseFeliciano A Serrano
Department of Medicine, University of Vermont, Burlington, Vermont, USA
Thromb J 5:7. 2007..To determine whether expression of FcGammaRIIA impacts platelet reactivity we quantified its expression and platelet reactivity in 33 patients with ESRD who were undergoing hemodialysis...
- Contrast-induced nephropathy: update with special emphasis on patients with diabetesRichard Solomon
Fletcher Allen Health Care, University of Vermont School of Medicine, UHC 2309, 1 South Prospect Street, Burlington, VT 05401, USA
Curr Diab Rep 7:454-8. 2007..There have been few new insights into pathogenesis; despite multiple strategies aimed at prophylaxis, very few have proven efficacious. This article reviews our current knowledge regarding CIN, with emphasis on patients with diabetes...
- Preventing contrast-induced nephropathy: problems, challenges and future directionsRichard Solomon
University of Vermont College of Medicine, Burlington, VT 05405 0068, USA
BMC Med 7:24. 2009..In this commentary, the pathogenesis and clinical relevance of contrast-induced nephropathy are reviewed. Prophylactic strategies are discussed with a focus on the use of meta-analysis of small single-center trials...
- Contrast-induced acute kidney injury (CIAKI)Richard Solomon
Department of Medicine, University of Vermont School of Medicine, 1 South Prospect Street, Burlington, VT 05401, USA
Radiol Clin North Am 47:783-8, v. 2009..After discussion of the reported incidence of CIAKI, an approach to prevention is briefly reviewed...
- Defining acute kidney injury: what is the most appropriate metric?Richard Solomon
Division of Nephrology and Hypertension, Fletcher Allen Health Care at the University of Vermont College of Medicine, VT, USA
Nat Clin Pract Nephrol 4:208-15. 2008..In this article we discuss the limitations and pitfalls of using serum markers to define AKI, and offer some suggestions for the future...
- Cardiac Angiography in Renally Impaired Patients (CARE) study: a randomized double-blind trial of contrast-induced nephropathy in patients with chronic kidney diseaseRichard J Solomon
Department of Renal Services, Fletcher Allen Health Care, University of Vermont, Burlington, VT 05401, USA
Circulation 115:3189-96. 2007..No direct comparisons exist of the renal tolerability of the low-osmolality contrast medium iopamidol with that of the iso-osmolality contrast medium iodixanol in high-risk patients...
- Contrast media and nephropathy: findings from systematic analysis and Food and Drug Administration reports of adverse effectsRichard Solomon
University of Vermont, Burlington, VT 05401, USA
Invest Radiol 41:651-60. 2006..Recent studies suggest differences in the incidence of contrast-induced nephropathy (CIN) among contrast media (CM)...
- The role of osmolality in the incidence of contrast-induced nephropathy: a systematic review of angiographic contrast media in high risk patientsRichard Solomon
Fletcher Allen Health Care, Burlington, Vermont, USA
Kidney Int 68:2256-63. 2005....
- Contrast-induced nephropathy and long-term adverse events: cause and effect?Richard J Solomon
Department of Renal Services, Fletcher Allen Health Care, Burlington, VT 05401, USA
Clin J Am Soc Nephrol 4:1162-9. 2009..The relationship of contrast-induced nephropathy (CIN) to long-term adverse events (AEs) is controversial. Although an association with AEs has been previously reported, it is unclear whether CIN is causally related to these AEs...
- N-acetylcysteine effect on serum creatinine and cystatin C levels in CKD patientsTariq Rehman
Division of Nephrology, Fletcher Allen Health Care and University of Vermont, Burlington, Vermont, USA
Clin J Am Soc Nephrol 3:1610-4. 2008..This confounding effect of N-acetylcysteine on serum creatinine has not been rigorously tested, however, in a population at risk for CIN and following doses of NAC currently recommended for prophylaxis of CIN...
- Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathyGeorge Bakris
Department of Medicine, Pritzker School of Medicine, University of Chicago, Chicago, Illinois, USA
Kidney Int 74:364-9. 2008..We conclude that telmisartan is superior to losartan in reducing proteinuria in hypertensive patients with diabetic nephropathy, despite a similar reduction in blood pressure...
- A randomized, double-blind, placebo-controlled trial of calcium acetate on serum phosphorus concentrations in patients with advanced non-dialysis-dependent chronic kidney diseaseWajeh Qunibi
Department of Medicine, University of Texas Health Sciences Center, 7703 Floyd Curl Drive, San Antonio, TX 78229, USA
BMC Nephrol 12:9. 2011..This trial was conducted to examine the efficacy and safety of calcium acetate in controlling serum phosphorus in pre-dialysis patients with CKD...
- Attenuation of platelet reactivity by enoxaparin compared with unfractionated heparin in patients undergoing haemodialysisAtul Aggarwal
Department of Medicine, University of Vermont College of Medicine, Burlington, VT, USA
Nephrol Dial Transplant 19:1559-63. 2004..Because both haemodialysis and unfractionated heparin (UFH) can increase platelet reactivity, we compared platelet reactivity during haemodialysis when patients were anticoagulated with UFH or enoxaparin...